Received Oct 31, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | UNK | — |
Shingrix was administered a 3rd time; This non-serious case was reported by a other health professional via call center representative and described the occurrence of extra dose administered in a patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received 2 doses on an unknown date). On an unknown date, the patient received the 3rd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced extra dose administered (Verbatim: Shingrix was administered a 3rd time). The outcome of the extra dose administered was not applicable. Additional Information: GSK Receipt Date: 20-OCT-2025 The reporter reported that Shingrix was administered a 3rd time to a patient, which led to extra dose administered The batch number was not provided and a request for this information has been made.